QL2106 vs tildrakizumab
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Psoriasis
Shared mechanism: IL-23 p19 · full Psoriasis pipeline
QL2106
Developed by Qilu Pharmaceutical
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: December 2027 · NCT07511647 (registry estimate)
No aligned efficacy figure on record for this race.
tildrakizumab · Ilumya
Marketed by Sun Pharmaceutical Industries and partners
NCT01729754 · Phase 3 · completed
This was a large, randomized, quadruple-blind, placebo- and active-controlled Phase 3 trial (N=1,090) in moderate-to-severe plaque psoriasis. The primary efficacy endpoints, PASI-75 and PGA clear/minimal at Week 12, were both statistically significant in favor of tildrakizumab 200 mg and 100 mg compared with placebo (p<0.001). The strong design and positive primary results provide high-quality evidence of treatment benefit.
Next expected readout: September 2028 · NCT05390515 (registry estimate)
Reported efficacy
Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)); Percentage of Participants With a Physician's Global Assessment (PGA) Score of Clear or Minimal With at Least a 2 Grade Reduction From Baseline at Week 12 (Base Study) (Baseline and Week 12 (or end of trial if prior to Week 12)); Number of Participants Experiencing an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to an Adverse Event Up to Week 12 (Base Study) (Up to 12 weeks); Number of Participants Discontinuing Study Drug Due to a Drug-Related Adverse Event (Base Study) (Up to 12 weeks): Percentage of Participants With Psoriasis Area Sensitivity Index 75 (PASI-75) Response at Week 12 (Base Study) (Week 12 (or end of trial if prior to Week 12)): Tildrakizumab 200 mg (Part 1) 62.3% | Tildrakizumab 100 mg (Part 1) 63.8% vs Placebo (Part 1) 5.8% (met)
Result source: NCT01722331
Results for Psoriasis
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | QL2106 | tildrakizumab |
|---|---|---|
| PASI 75 | —Trial running · NCT07511647 | 66.3% vs 4.4%+61.9 vs placeboNCT0122573131 other results
|
| PASI 90 | —Trial running · NCT07511647 | 38.6% vs 2.4%+36.2 vs placeboNCT012257313 other results
|
| PASI 100 | —Trial running · NCT07511647 | 14.8% vs 0%+14.8 vs placeboNCT012257313 other results
|
| sPGA 0/1 | —Trial running · NCT07511647 | 61.8% vs 2.2%+59.6 vs placeboNCT012257313 other results
|
| DLQI, change | —Trial running · NCT07511647 | -8.5 vs 1−9.5 vs placeboNCT012257313 other results
|
PASI 75
- QL2106
- —Trial running · NCT07511647
- tildrakizumab
- 66.3% vs 4.4%+61.9 vs placeboNCT01225731
31 other results
- 74.4% vs 4.4% NCT01225731
- 64.4% vs 4.4% NCT01225731
- 33.3% vs 4.4% NCT01225731
- 67.0% vs 4.9% NCT01225731
- 60.7% vs 4.4% NCT01225731
- 61.4% vs 4.8% NCT01225731
- 47.1% vs 4.7% NCT01225731
- 25% vs 2.3% NCT01225731
- 11.2% vs 0% NCT01225731
- 1.1% vs 0% NCT01225731
- 76.2% vs 4.9% NCT01225731
- 72.1% vs 4.4% NCT01225731
- 73.5% vs 4.8% NCT01225731
- 61.5% vs 4.7% NCT01225731
- 30.9% vs 2.3% NCT01225731
- 3.5% vs 0% NCT01225731
- 0% vs 0% NCT01225731
- 65.5% vs 4.9% NCT01225731
- 58.9% vs 4.4% NCT01225731
- 59.8% vs 4.8% NCT01225731
- 35.2% vs 4.7% NCT01225731
- 20.9% vs 2.3% NCT01225731
- 11.2% vs 0% NCT01225731
- 1.1% vs 0% NCT01225731
- 35% vs 4.9% NCT01225731
- 23.8% vs 4.4% NCT01225731
- 25% vs 4.8% NCT01225731
- 12.5% vs 4.7% NCT01225731
- 12.5% vs 2.3% NCT01225731
- 0% vs 0% NCT01225731
- 0% vs 0% NCT01225731
PASI 90
- QL2106
- —Trial running · NCT07511647
- tildrakizumab
- 38.6% vs 2.4%+36.2 vs placeboNCT01225731
3 other results
- 52.4% vs 2.4% NCT01225731
- 25.3% vs 2.4% NCT01225731
- 12.5% vs 2.4% NCT01225731
PASI 100
- QL2106
- —Trial running · NCT07511647
- tildrakizumab
- 14.8% vs 0%+14.8 vs placeboNCT01225731
3 other results
- 16.7% vs 0% NCT01225731
- 9.2% vs 0% NCT01225731
- 5% vs 0% NCT01225731
sPGA 0/1
- QL2106
- —Trial running · NCT07511647
- tildrakizumab
- 61.8% vs 2.2%+59.6 vs placeboNCT01225731
3 other results
- 74.4% vs 2.2% NCT01225731
- 57.8% vs 2.2% NCT01225731
- 33.3% vs 2.2% NCT01225731
DLQI, change
- QL2106
- —Trial running · NCT07511647
- tildrakizumab
- -8.5 vs 1−9.5 vs placeboNCT01225731
3 other results
- -8.8 vs 1 NCT01225731
- -9.2 vs 1 NCT01225731
- -4.9 vs 1 NCT01225731
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
QL2106: no structured comparison results are available for Psoriasis.
Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.
safety
Coverage. QL2106: 0 of 4 rows · tildrakizumab: 4 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | tildrakizumab |
|---|---|
| Dropout rate | —100 mga NCT01729754 · Phase 3 · monotherapy show 24 more results—200 mg NCT01729754 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy 15.7%100 mg NCT03897075 · Phase 3 —100 mg NCT03897075 · Phase 3 16.7% NCT04271540 · Phase 4 · registry result, not featured evidence 0% NCT04541329 · Phase 4 · registry result, not featured evidence 18.2%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.3%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 5.4%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 4.8%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100 mga NCT01729754 · Phase 3 · monotherapy show 24 more results—200 mg NCT01729754 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —200 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT03897075 · Phase 3 —100 mg NCT03897075 · Phase 3 — NCT04271540 · Phase 4 · registry result, not featured evidence — NCT04541329 · Phase 4 · registry result, not featured evidence 1.8%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence —100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.2%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence —200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.2%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence —25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.4%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence —5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 6.2%100 mga NCT01729754 · Phase 3 · monotherapy show 24 more results4.9%200 mg NCT01729754 · Phase 3 · monotherapy 1.6%100 mg NCT01722331 · Phase 3 · monotherapy 1.9%100 mg NCT01722331 · Phase 3 · monotherapy 4.4%100 mg NCT01722331 · Phase 3 · monotherapy 2.6%200 mg NCT01722331 · Phase 3 · monotherapy 2.2%200 mg NCT01722331 · Phase 3 · monotherapy 5.8%200 mg NCT01722331 · Phase 3 · monotherapy —100 mg NCT03897075 · Phase 3 5.9%100 mg NCT03897075 · Phase 3 0% NCT04271540 · Phase 4 · registry result, not featured evidence 0% NCT04541329 · Phase 4 · registry result, not featured evidence 7.3%100 mg NCT03718299 · Phase 4 · registry result, not featured evidence 1.1%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 3.9%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.5%100 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.3%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 3.8%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 2.7%200 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.1%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 5.3%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 1.1%25 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence 0%5 mg NCT01225731 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100 mga nasopharyngitis 23% (placebo 7.7%) headache 6% (placebo 3.8%) arthralgia 5.3% (placebo 1.9%) NCT01729754 · Phase 3 · monotherapy show 22 more results200 mg nasopharyngitis 22.6% (placebo 7.7%) headache 5.7% (placebo 3.8%) upper respiratory tract infection 5.1% (placebo 0.6%) NCT01729754 · Phase 3 · monotherapy 100 mg nasopharyngitis 7.8% (placebo 5.2%) upper respiratory tract infection 3.2% (placebo 5.8%) psoriasis 0.6% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg nasopharyngitis 6.4% (placebo 5.2%) upper respiratory tract infection 4.3% (placebo 5.8%) psoriasis 0.5% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg nasopharyngitis 15.2% (placebo 5.2%) upper respiratory tract infection 8.2% (placebo 5.8%) psoriasis 2.8% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg nasopharyngitis 6.5% (placebo 5.2%) upper respiratory tract infection 4.9% (placebo 5.8%) psoriasis 0% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg upper respiratory tract infection 5.4% (placebo 5.8%) nasopharyngitis 4.6% (placebo 5.2%) psoriasis 0.8% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 200 mg nasopharyngitis 12.2% (placebo 5.2%) upper respiratory tract infection 10.3% (placebo 5.8%) psoriasis 2.5% (placebo 5.2%) NCT01722331 · Phase 3 · monotherapy 100 mg covid-19 11.8% (placebo 10.4%) skin and subcutaneous tissue disorders 9.8% (placebo 4.2%) upper respiratory tract infection 9.8% (placebo 8.3%) NCT03897075 · Phase 3 covid infection 9.7% NCT04271540 · Phase 4 · registry result, not featured evidence 100 mg psoriasis 12.7% hypertension 9.1% dermatitis 5.5% NCT03718299 · Phase 4 · registry result, not featured evidence 100 mg nasopharyngitis 14.6% (placebo 20%) diarrhoea 6.7% (placebo 6.7%) headache 6.7% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 22.2% (placebo 20%) headache 8.5% (placebo 8.9%) back pain 5.2% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 100 mg nasopharyngitis 8.8% (placebo 20%) back pain 3.6% (placebo 0%) headache 3.6% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 12.8% (placebo 20%) headache 8.1% (placebo 8.9%) pruritus 4.7% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 16.5% (placebo 20%) gastroenteritis 6.3% (placebo 2.2%) upper respiratory tract infection 5.1% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 200 mg nasopharyngitis 6.7% (placebo 20%) upper respiratory tract infection 4% (placebo 0%) bronchiitis 2.7% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 13.2% (placebo 20%) diarrhoea 5.5% (placebo 6.7%) headache 5.5% (placebo 8.9%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 25.5% (placebo 20%) gastroenteritis 5.3% (placebo 2.2%) back pain 4.3% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 25 mg nasopharyngitis 6.9% (placebo 20%) back pain 3.4% (placebo 0%) bronchiitis 2.3% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 16.7% (placebo 20%) bronchiitis 7.1% (placebo 4.4%) cough 7.1% (placebo 4.4%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg nasopharyngitis 23.1% (placebo 20%) acute tonsilitis 7.7% (placebo 0%) blood pressure systolic increased 7.7% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence 5 mg abdominal pain upper 8.3% (placebo 0%) back pain 8.3% (placebo 0%) dyspnoea 8.3% (placebo 0%) NCT01225731 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
tildrakizumab
show 5 more results
show 5 more results
show 11 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
show 5 more results
show 11 more results
+ 33 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: QL2106's landscape · tildrakizumab's landscape